Discover 1,289 paid clinical trials in Columbus, Ohio. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Columbus hosts a variety of active clinical studies, including for conditions such as diabetes, asthma, and cardiovascular diseases. The city's prominent healthcare institutions are recruiting participants, both as healthy volunteers seeking paid research opportunities and individuals in need of trials for specific conditions, offering access to new and innovative treatments and therapies.
Filter
2
Filter results
Results: 1,289
Active & Responsive
A Double Blind Study Performed to Evaluate the Efficacy and the Safety of EscharEx in Debridement of VLU (VALUE)
for
Venous Leg Ulcer (VLU)
Location: Circleville OH, Newark NJ, New York NY, Lake Success NY,
Sponsor: MediWound Ltd
Sex: All
Age: 18+
Code: NCT06568627
Phase3, Recruiting
Active & Responsive
Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention
for
Percutaneous Coronary Intervention,
Location: Springfield OH, Zanesville OH, Richmond IN, Canton OH,
Sponsor: Duke University
Sex: All
Age: 18+
Code: NCT06909565
Recruiting
Active & Responsive
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events
for
Cardiovascular Disease
Location: Marion OH, Lima OH, Cincinnati OH, Richmond IN,
Sponsor: Amgen
Sex: All
Age: 50 - 70+
Code: NCT07136012
Phase3, Recruiting
Active & Responsive
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
for
Obesity, Heart Failure
Location: Marion OH, Vandalia OH, Dayton OH, Maumee OH,
Sponsor: Novo Nordisk A/S
Sex: All
Age: 18+
Code: NCT07567001
Phase3, Recruiting
Active & Responsive
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
for
Anatomic Stage II Breast Cancer AJCC v8,
Location: Lexington KY, Dearborn MI, Detroit MI, Canton MI,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT06058377
Phase3, Recruiting
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Study Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis
for
Chronic Obstructive Pulmonary Disease With Chronic Bronchitis
Location: Columbus OH, DuBois PA, Boerne TX
Sponsor: UCB Biopharma SRL
Sex: All
Age: 40 - 70+
Code: NCT07725939
Phase2, Recruiting
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
for
Hidradenitis Suppurativa (HS)
Location: Columbus OH, Bexley OH, Cincinnati OH, Indianapolis IN,
Sponsor: Incyte Corporation
Sex: All
Age: 18+
Code: NCT06855498
Phase3, Recruiting
Letrozole in Uterine Leiomyosarcoma
for
Uterine Leiomyosarcoma
Location: Columbus OH, Marion OH, Fostoria OH, Fremont OH,
Sponsor: GOG Foundation
Sex: Female
Age: 18+
Code: NCT05649956
Phase2, Recruiting
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
for
Non-Muscle Invasive Bladder Urothelial Carcinoma,
Location: Columbus OH, Dublin OH, Marion OH, Mansfield OH,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT06770582
Phase2, Recruiting
Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy